Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39,094 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.
Li J, Bai Y, Chen Z, Ying J, Guo Y, Fang W, Zhang F, Xiong J, Zhang T, Meng Z, Zhang J, Ren Z, Hao C, Chen Y, Lin X, Pan H, Zhou F, Li X, Yu F, Zhang J, Zhang Z, Qin S. Li J, et al. Among authors: zhang f, zhang t, zhang j, zhang z. Cancer Immunol Immunother. 2024 Sep 5;73(11):219. doi: 10.1007/s00262-024-03806-2. Cancer Immunol Immunother. 2024. PMID: 39235596 Free PMC article. Clinical Trial.
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice.
Li J, Wang Z, Zhong H, He Y, Zhang C, Niu Z, Yang S, Zhang T, Zhu L, Shu Y, Gao Y, Peng J, Song Y, Li J, Yuan Y, Zhang H, Yu G, Hua Y, Xiao J, Fu J, Zheng Y, Xue H, Luo X, Shi M, Su W, Qin S. Li J, et al. Among authors: zhang c, zhang t, zhang h. Oncologist. 2024 Aug 5;29(8):e1012-e1019. doi: 10.1093/oncolo/oyae073. Oncologist. 2024. PMID: 38642091 Free PMC article. Clinical Trial.
S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study.
Wang X, Feng G, Yang X, Yu N, Zheng Z, Li J, Kang X, Chen X, Zhang R, Li Y, Wang Z, Deng L, Zhang T, Liu W, Wang J, Wang W, Feng Q, Xiao Z, Zhou Z, Bi N, Li Y, Qin J. Wang X, et al. Among authors: zhang r, zhang t. Cancer Biol Ther. 2024 Dec 31;25(1):2417464. doi: 10.1080/15384047.2024.2417464. Epub 2024 Oct 27. Cancer Biol Ther. 2024. PMID: 39462770 Free PMC article.
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.
Wang F, Shen L, Guo W, Liu T, Li J, Qin S, Bai Y, Chen Z, Wang J, Pan Y, Shu Y, Zhao F, Cheng Y, Ye F, Gu K, Zhang T, Pan H, Zhong H, Zhou F, Qin Y, Yang L, Mao W, Li Q, Dai W, Li W, Wang S, Tang Y, Ma D, Yin X, Deng Y, Yuan Y, Li M, Hu W, Chen D, Li G, Liu Q, Tan P, Fan S, Shi M, Su W, Xu RH. Wang F, et al. Among authors: zhang t. Nat Med. 2024 Aug;30(8):2189-2198. doi: 10.1038/s41591-024-02989-6. Epub 2024 Jun 1. Nat Med. 2024. PMID: 38824242 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
Wu F, Jiang T, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J, Bai X, Ren S, Zhou C; CameL Study Group. Wu F, et al. Among authors: zhang w, zhang t, zhang y. Cancer Commun (Lond). 2022 Dec;42(12):1331-1346. doi: 10.1002/cac2.12383. Epub 2022 Nov 4. Cancer Commun (Lond). 2022. PMID: 36331328 Free PMC article.
39,094 results
You have reached the last available page of results. Please see the User Guide for more information.